Precision oncology in urogenital and gynecological tumors (Ongoing)

Posted On 2021-08-19 15:31:35



The series on “Precision oncology in urogenital and gynecological tumors” is edited by Drs Elie Rassy (Gustave Roussy Institut, France), Nicholas Pavlidis (University of Ioannina, Greece), Stergios Boussios (Medway NHS Foundation Trust, UK), and Joseph Kattan (Saint Joseph University, Lebanon).

Elie Rassy, MD, MSc, MPH
Department of Cancer Medicine, Gustave Roussy Institut, Villejuif, France

Dr. Rassy is currently a senior resident (clinical and research activity) at Gustave Roussy, one of the world’s leading cancer-research institutes and the largest comprehensive cancer center in Europe. His current scope of research focuses on precision oncology and early-stage cancer treatments. As a young medical oncology fellow, he has contributed to over 150 peer-reviewed publications and several book chapters, including the Oxford Textbook of Oncology, mainly focusing on cancers of unknown primary, urogenital and gynecological tumors. He is an active speaker, lecturing on subjects related to these malignancies nationally and internationally.

Nicholas Pavlidis, MD, PhD, FRCP (Hon)
Medical School, University of Ioannina, Ioannina, Greece

Dr. Pavlidis is Emeritus Professor at University of Ioannina, Ioannina, Greece and Dean of European School of Oncology College, Milan, Italy. He has served as Secretary of ECTG, NDDO, EORTC, Amsterdam, Netherlands and Chairman of ESMO Guidelines Task Force, Lugano. Switzerland as well as Chairman, ESMO-ASCO Global Curriculum Task Force, Lugano. He has been Coordinator for ESO Career Development Program, Milan, Italy; Dean of Medical School, University of Cyprus, Nicosia, Cyprus; and Councilor of ACCOE, Brussels, Belgium. He is also the Editor in Chief,of Cancer Treatment Reviews, Elsevier, Oxford.

Stergios Boussios, MD, MSc, PhD, MRCP (London)
Department of Medical Oncology, Medway NHS Foundation Trust, Kent, UK

Dr. Boussios currently serves as consultant at the Department of Medical Oncology, Medway NHS Foundation Trust, Kent Oncology Centre, UK, and is research lead in the CUP. He is actively involved in translational research in cancer and is principal investigator in phase I-III studies. His research interests include individualization of patient treatment and targeted therapies in gynecological cancers, CUP, urological cancers, new drug development and cancer diagnosed in pregnancy.

Dr. Boussios was awarded European School of Oncology (ESO) and Hellenic Society of Medical Oncology (HeSMO) fellowships for clinical and laboratory research at the Royal Marsden Hospital, London, United Kingdom (2014-2015), and specialized in ovarian cancer.

And he was awarded the HeSMO second award for his research on CUP in the 2016 National Congress. Dr. Boussios was selected by the European Society of Medical Oncology (ESMO) Fellowship and Award Committee to be part of the ESMO Leaders Generation Programme in 2017. Dr. Boussios has been involved in several international and national specialist groups including the European Network of Gynecological Oncological Trial Groups (ENGOT), and the Gynecological working group of the Hellenic Cooperative Oncology Group (HeCOG). He is also an ESMO and HeSMO member. Dr. Boussios is an author of over 40 peer-reviewed publications, and has been guest editor or editorial board member of many highly esteemed journals.

Joseph Kattan, MD, MSc
Department of Hematology-Oncology, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon

Dr. Kattan is Head of Hematology-Oncology Department at Hotel-Dieu de France University Hospital in Beirut, Lebanon since 2014. He graduated in Medicine in 1986 and obtained a specialization in Medical Oncology in 1993 and appointed as Professor of Hematology-Oncology at Saint Joseph University of Beirut in 1994. In 1988, he began 5 years of training at Gustave-Roussy Institute, Villejuif, France. His main fields of interest are genito-urinary, lung, gastro-intestinal tumors, gynecology, intensified therapy and supportive care. He graduated from Paris-Sud University in Oncology in 1989, in Immunology in 1991, and in Hematology in 1993. He is responsible of numerous courses and programs in Hematology-oncology in Lebanon at Saint-Joseph University, including the president of the Continuous Medical Education Program of Saint Joseph University, and in France at Paris XI University.

He is member or former member of the Editorial boards of: Bulletin du Cancer, Lebanese Medical Journal, Cancer Letter and the International Journal of Hematology and Oncology.

He is the author of more than 300 peer reviewed articles published in international journal covering diverse topics such as pharmacology, drug development, genito-urinary, gastro-intestinal oncology and supportive care.

He is member of international and regional scientific societies: ASCO, ESMO, MASCC, SFC, EHA, SIOG, SLC and LSMO, and a founder member of Cancer Research Group (CRG) Collaborative Group. He is currently the general secretary of Cancer Research Group.

Series outline:

  1. Introduction to the series
  2. Biomarkers of response to immune checkpoint inhibitors in bladder cancer
  3. Metagenomics in renal cell carcinoma
  4. Antibody-drug conjugates in urogenital tumors
  5. Radiomics in prostate cancer
  6. Current evidence of BRCA mutations in genitourinary and gynecologic tumors
  7. Clinical implications of liquid biopsies in urogenital tumors
  8. Clinical implications of liquid biopsy in gynecologic tumors
  9. Precision oncology in renal cell carcinoma with sarcomatoid features
  10. Extended Carboplatin infusion in gynecological cancer: does it reduce the hypersensitivity reaction?

Disclosure:
The series “Precision oncology in urogenital and gynecological tumors” was commissioned by the editorial office, Precision Cancer Medicine without any sponsorship or funding. Drs Elie Rassy, Nicholas Pavlidis, Stergios Boussios, and Joseph Kattan are serving as the unpaid Guest Editors for the series.